Matching-adjusted indirect comparison (MAIC) of deucravacitinib versus adalimumab for the treatment of patients with moderate to severe plaque psoriasis over 2 years. SKIN The Journal of Cutaneous Medicine, [S. l.], v. 7, n. 2, p. s112, 2023. DOI: 10.25251/skin.7.supp.112. Disponível em: https://skin.dermsquared.com/skin/article/view/1995. Acesso em: 29 apr. 2026.